Mar Tintore

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. ncbi request reprint Is optic neuritis more benign than other first attacks in multiple sclerosis?
    Mar Tintore
    Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 57:210-5. 2005
  2. ncbi request reprint Baseline MRI predicts future attacks and disability in clinically isolated syndromes
    M Tintore
    Unit of Clinical Neuroimmunology Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Neurology 67:968-72. 2006
  3. ncbi request reprint Early MS treatment
    M Tintore
    Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, 08035 Barcelona, Spain
    Int MS J 14:5-10. 2007
  4. ncbi request reprint Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
    M Tintore
    Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Neurology 70:1079-83. 2008
  5. doi request reprint Rationale for early intervention with immunomodulatory treatments
    Mar Tintore
    Unitat de Neuroimmunologia Clinica UNIC, Edif Escola d Infermeria Planta 2, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    J Neurol 255:37-43. 2008
  6. doi request reprint Brainstem lesions in clinically isolated syndromes
    M Tintore
    Unitat de Neuroimmunologia Clinica UNIC, Edif Escola d Infermeria Planta 2, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Neurology 75:1933-8. 2010
  7. doi request reprint New treatment measurements for treatment effects on relapses and progression
    Mar Tintore
    Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Centre of Catalonia CEM Cat Hospital Vall d Hebron, Barcelona, Spain
    J Neurol Sci 274:80-3. 2008
  8. doi request reprint New options for early treatment of multiple sclerosis
    Mar Tintore
    Multiple Sclerosis Center of Catalonia, Clinical Neuroimmunology Multiple Sclerosis Unit, Vall d Hebron University Hospital, Barcelona, Spain
    J Neurol Sci 277:S9-S11. 2009
  9. ncbi request reprint Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients
    Jordi Rio
    2TM planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 59:344-52. 2006
  10. doi request reprint Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision
    Carmen Tur
    Clinical Neuroimmunology Unit, Multiple Sclerosis Centre of Catalonia Centre d Esclerosi Múltiple de Catalunya, CEM Cat, Vall d Hebron University Hospital, Barcelona, Spain
    Mult Scler 18:1193-6. 2012

Collaborators

Detail Information

Publications54

  1. ncbi request reprint Is optic neuritis more benign than other first attacks in multiple sclerosis?
    Mar Tintore
    Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 57:210-5. 2005
    ..Optic neuritis has a smaller risk for conversion to multiple sclerosis. Nevertheless, MRI at baseline, not CIS topography, appears to be the crucial issue at multiple sclerosis presentation...
  2. ncbi request reprint Baseline MRI predicts future attacks and disability in clinically isolated syndromes
    M Tintore
    Unit of Clinical Neuroimmunology Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Neurology 67:968-72. 2006
    ..To determine the relation between baseline MRI and both conversion to multiple sclerosis (MS) and development of disability in a cohort of patients with clinically isolated syndromes (CIS)...
  3. ncbi request reprint Early MS treatment
    M Tintore
    Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, 08035 Barcelona, Spain
    Int MS J 14:5-10. 2007
    ..While MRI can be used to determine who will benefit most from treatment, the use of other biological markers needs to be confirmed in different settings before they can be used in clinical practice...
  4. ncbi request reprint Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
    M Tintore
    Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Neurology 70:1079-83. 2008
    ..To evaluate whether oligoclonal bands (OB) add information to MRI in predicting both a second attack and development of disability in patients with clinically isolated syndromes (CIS)...
  5. doi request reprint Rationale for early intervention with immunomodulatory treatments
    Mar Tintore
    Unitat de Neuroimmunologia Clinica UNIC, Edif Escola d Infermeria Planta 2, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    J Neurol 255:37-43. 2008
    ..It is concluded that choosing the right time to introduce treatment is critically important for outcome and the earlier treatment is initiated, the better the outcome...
  6. doi request reprint Brainstem lesions in clinically isolated syndromes
    M Tintore
    Unitat de Neuroimmunologia Clinica UNIC, Edif Escola d Infermeria Planta 2, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Neurology 75:1933-8. 2010
    ..Number of baseline lesions has been shown to predict future attacks and disability in clinically isolated syndromes (CIS)...
  7. doi request reprint New treatment measurements for treatment effects on relapses and progression
    Mar Tintore
    Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Centre of Catalonia CEM Cat Hospital Vall d Hebron, Barcelona, Spain
    J Neurol Sci 274:80-3. 2008
    ..MRI has also been of great help in monitoring the effect of immunomodulatory drugs in CIS or RRMS clinical trials. Its role to predict treatment response is still controversial on an individual basis...
  8. doi request reprint New options for early treatment of multiple sclerosis
    Mar Tintore
    Multiple Sclerosis Center of Catalonia, Clinical Neuroimmunology Multiple Sclerosis Unit, Vall d Hebron University Hospital, Barcelona, Spain
    J Neurol Sci 277:S9-S11. 2009
    ..An application for an extension of the approved indication of glatiramer acetate to the treatment of patients with a first clinical event suggestive of multiple sclerosis has been filed with the regulatory authorities...
  9. ncbi request reprint Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients
    Jordi Rio
    2TM planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 59:344-52. 2006
    ..Early identification of nonresponder patients is crucial to try different therapeutic approaches. We investigated various criteria of treatment response to assess which criterion better identifies patients with a poor response...
  10. doi request reprint Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision
    Carmen Tur
    Clinical Neuroimmunology Unit, Multiple Sclerosis Centre of Catalonia Centre d Esclerosi Múltiple de Catalunya, CEM Cat, Vall d Hebron University Hospital, Barcelona, Spain
    Mult Scler 18:1193-6. 2012
    ..The decision to discontinue natalizumab treatment is complex, even when clear PML risk rates are described. Clinical outcomes and doctors' idiosyncrasies play a crucial part in patients' final choice...
  11. ncbi request reprint Interferon beta in secondary progressive multiple sclerosis : daily clinical practice
    Jordi Rio
    2a planta EUI, Unitat de Neuroimmunología Clínica Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035 Barcelona, Spain
    J Neurol 254:849-53. 2007
    ..We present the data from a cohort of secondary progressive multiple sclerosis (SPMS) patients treated with interferon beta (IFNbeta-1b) at our MS clinic...
  12. ncbi request reprint Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes
    Jaume Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Arch Neurol 61:222-4. 2004
    ....
  13. pmc Serum biomarker gMS-Classifier2: predicting conversion to clinically definite multiple sclerosis
    Georgina Arrambide
    Department of Neurology Neuroimmunology, Multiple Sclerosis Centre of Catalonia Cemcat, Vall d Hebron University Hospital and Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain
    PLoS ONE 8:e59953. 2013
    ..IgM against glycan P63 was identified in clinically isolated syndromes (CIS) and included in gMS-Classifier2, an algorithm designed with the aim of identifying patients at risk of a second demyelinating attack...
  14. ncbi request reprint Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis
    Carlos Nos
    Unitat de Neuroimmunologia Clinica, Hospital Vall d Hebron, Barcelona, Spain
    Mult Scler 10:413-6. 2004
    ....
  15. ncbi request reprint Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre
    Jordi Rio
    2a planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035, Barcelona, Spain
    J Neurol 252:795-800. 2005
    ..We present the data of our cohort of relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon beta (IFNbeta)...
  16. ncbi request reprint Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 11:306-9. 2005
    ....
  17. ncbi request reprint Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone
    Nieves Téllez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, 08035 Barcelona, Spain
    Mult Scler 12:487-94. 2006
    ..Fatigue is one of the most limiting symptoms in multiple sclerosis (MS) and the mechanisms underlying its origin are poorly understood. Our aim was to test whether fatigue in MS is associated with endocrine markers...
  18. doi request reprint Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona 08035, Spain
    Brain 133:1082-93. 2010
    ....
  19. ncbi request reprint Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 52:400-6. 2002
    ....
  20. doi request reprint TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis
    Manuel Comabella
    Department of Neurology Neuroimmunology, Centre d esclerosi multiple de Catalunya, Cemcat, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Neurology 80:2010-6. 2013
    ....
  21. doi request reprint A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis
    Alex Rovira
    Magnetic Resonance Unit, Department of Radiology, Hospital Vall d Hebron, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Arch Neurol 66:587-92. 2009
    ....
  22. ncbi request reprint [Long-term effect of neutralizing antibodies to interferon beta-1 b in patients with multiple sclerosis]
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Med Clin (Barc) 124:140-1. 2005
    ..Our goal was to evaluate the relation between the presence of neutralizing antibodies (NABs) to interferon beta-1b in multiple sclerosis (MS) patients and the clinical evolution in the following years...
  23. ncbi request reprint The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta
    Pablo Villoslada
    Neuroimmunology Unit, Hospital Vall d Hebron, Barcelona, Spain
    J Neuroimmunol 130:194-201. 2002
    ..Similarly, no difference in the distribution of responders and nonresponders to interferon-beta (IFNB) therapy, as defined by primary and secondary end points, was observed when individuals were stratified according to HLA-DR2 status...
  24. doi request reprint Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up
    Carmen Tur
    Multiple Sclerosis Centre of Catalonia, Autonomous University of Barcelona, Centre d Anàlisi i Recerca en Neuroimatge i Esclerosi Mùltiple Vall d Hebron University Hospital, Escola Universitària d Infermeria 2ª planta, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
    Arch Neurol 68:1421-7. 2011
    ....
  25. doi request reprint B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    J Neuroimmunol 223:135-7. 2010
    ....
  26. ncbi request reprint The immune response against herpesvirus is more prominent in the early stages of MS
    P Villoslada
    Neuroimmunology Unit, Hospital Vall d Hebron, Barcelona, Spain
    Neurology 60:1944-8. 2003
    ..To assess antibody levels against human herpesvirus type 6 (HHV-6), Epstein-Barr virus (EBV), and Chlamydia pneumoniae (CP) in serum from individuals in the early and late phase of MS...
  27. pmc Risk acceptance in multiple sclerosis patients on natalizumab treatment
    Carmen Tur
    Multiple Sclerosis Centre of Catalonia Cemcat, Department of Neurology Neuroimmunology, Vall d Hebron University Hospital, Barcelona, Spain
    PLoS ONE 8:e82796. 2013
    ..We aimed to investigate the ability of natalizumab (NTZ)-treated patients to assume treatment-associated risks and the factors involved in such risk acceptance...
  28. doi request reprint Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes
    Angela Vidal-Jordana
    Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Mult Scler 19:1175-81. 2013
    ..Investigation of atrophy data from a pivotal natalizumab trial has demonstrated an increased rate of volume loss, compared to placebo, after the first year of therapy. It was considered to be probably due to a pseudoatrophy effect...
  29. ncbi request reprint Altered maturation of circulating dendritic cells in primary progressive MS patients
    Cristina Lopez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, HUVH, Barcelona, Spain
    J Neuroimmunol 175:183-91. 2006
    ..These results suggest an impaired maturation state of DC in PPMS patients, and a beneficial effect of IFN-beta favouring the survival of PDC and promoting a Th2 environment...
  30. ncbi request reprint Unconventional therapy in multiple sclerosis
    Jaume Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 9:320-2. 2003
    ..The use of unconventional therapies is growing in western countries. Few studies on their frequency and rationale among multiple sclerosis (MS) patients have been carried out in Europe...
  31. doi request reprint A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
    X Montalban
    Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Centre of Catalonia CEM Cat, Barcelona, Spain
    Mult Scler 15:1195-205. 2009
    ..Positive effects of interferon beta on secondary clinical and magnetic resonance imaging outcomes were observed, but a beneficial effect on Expanded Disability Status Scale progression was not demonstrated...
  32. doi request reprint Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?
    R Pelayo
    Multiple Sclerosis Center of Catalonia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mult Scler 16:55-61. 2010
    ..However, the utility of MMEPs is limited by the low percentage of CIS patients having the three abnormal at baseline...
  33. ncbi request reprint Decreased MMP-9 production in primary progressive multiple sclerosis patients
    J Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital Vail d Hebron, Barcelona, Espanya
    Mult Scler 10:376-80. 2004
    ..However, data regarding primary progressive (PP) MS is scarce...
  34. doi request reprint Multiple sclerosis: Lesion location may predict disability in multiple sclerosis
    Jaume Sastre-Garriga
    Centre d esclerosi multiple de Catalunya, Hospital Universitari Vall d Hebron, Passeig de la Vall d Hebron 119 129, Barcelona, Spain
    Nat Rev Neurol 6:648-9. 2010
    ..Using a lesion probability mapping approach, researchers have identified brain regions where the presence of MS lesions predicts an early need for bilateral walking support...
  35. doi request reprint Early onset multiple sclerosis: the role of gender
    Mar Tintore
    Multiple Sclerosis Center of Catalonia, Clinical Neuroimmunology Multiple Sclerosis Unit, Vall d Hebron University Hospital, Barcelona, Spain
    J Neurol Sci 286:31-4. 2009
    ..Sex hormones may have immunologic implications, but more data are needed to explain the female predominance and its changes over time...
  36. doi request reprint Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 14:479-84. 2008
    ....
  37. ncbi request reprint Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?
    N Tellez
    Unitat de Neuroimmunologia Clinica, Edif EUI, Planta 2, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, 08035 Barcelona, Spain
    Mult Scler 11:198-202. 2005
    ..As a symptom of multiple sclerosis (MS), fatigue is difficult to manage because of its unknown etiology, the lack of efficacy of the drugs tested to date and the absence of consensus about which would be the ideal measure to assess fatigue...
  38. ncbi request reprint Fatigue in multiple sclerosis persists over time: a longitudinal study
    N Tellez
    2a planta EUI Unitat de Neuroimmunología, Clínica Hospital, Universitari Vall d Hebron Ps, Vall d Hebron 119 120, 08035, Barcelona, Spain
    J Neurol 253:1466-70. 2006
    ..The aim of our study was to investigate changes in fatigue in a large cohort of MS patients and to determine the relationship between changes in disability and depression with changes in fatigue severity...
  39. ncbi request reprint [Multiple sclerosis epidemiological situation update: pertinence and set-up of a population based registry of new cases in Catalonia]
    S Otero
    Servicio de Medicina Preventiva y Epidemiologia, Hospital General Universitari Vall d Hebron, Barcelona, Espana
    Rev Neurol 50:623-33. 2010
    ..The few prospective studies in our area together with the increase in the disease in other regions, justifies an epidemiological MS project in order to describe the incidence and temporal trends of MS...
  40. ncbi request reprint Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort
    R Pelayo
    Department of Neurology, Unit of Clinical Neuroinmunology, Hospital Universitari Vall d Hebron, Universitat Autonoma UAB, Barcelona, Spain
    Mult Scler 13:731-6. 2007
    ..There are differences between several studies in the definition, and, therefore, the prevalence of these so-called atypical CIS. Consensus on the denomination and definition of these syndromes must be reached...
  41. ncbi request reprint Long-term emotional state of multiple sclerosis patients treated with interferon beta
    J Porcel
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vail d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Mult Scler 12:802-7. 2006
    ..To assess the long-term emotional state of multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) for at least four years...
  42. doi request reprint Measures in the first year of therapy predict the response to interferon beta in MS
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 15:848-53. 2009
    ..Hence, the aim of this study was to investigate magnetic resonance imaging (MRI) and clinical predictors of response during the first 12 months of therapy...
  43. doi request reprint Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Edif EUI 2a planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    J Neurol 255:1136-41. 2008
    ....
  44. ncbi request reprint The basal ganglia: a substrate for fatigue in multiple sclerosis
    N Tellez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    Neuroradiology 50:17-23. 2008
    ..We aimed to study the relationship between fatigue in MS and the presence of focal dysfunction in the basal ganglia and frontal white matter...
  45. ncbi request reprint Serial proton spectroscopy, magnetization transfer ratio and T 2 relaxation in pseudotumoral demyelinating lesions
    M Gràcia Cucurella
    Unitat de Ressonància Magnètica Vall d Hebron, Institut de Diagnostic per la Imatge, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    NMR Biomed 15:284-92. 2002
    ..Thus, the evolution of this kind of lesion should be kept in mind when considering lesion volume from T1-weighted images as a marker of disability or irreversible cellular destruction in MS...
  46. ncbi request reprint FXTAS in spanish patients with ataxia: support for female FMR1 premutation screening
    Laia Rodriguez-Revenga
    Biochemistry and Molecular Genetics Department, Hospital Clinic, Barcelona, Spain
    Mol Neurobiol 35:324-8. 2007
    ..Early diagnosis of these patients benefits not only them but also the rest of the family that should be advised for the fragile X syndrome...
  47. ncbi request reprint New diagnostic criteria for multiple sclerosis: application in first demyelinating episode
    M Tintore
    Clinical Neuroimmunology Unit, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Neurology 60:27-30. 2003
    ....
  48. doi request reprint MRI criteria for MS in patients with clinically isolated syndromes
    X Montalban
    Unit of Clinical Neuroimmunology, EUI 2 P, Hospital Universitari Vall d Hebron, Paseig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Neurology 74:427-34. 2010
    ..New data that are now published were reviewed and discussed and together with a new proposal are integrated in this position paper...
  49. doi request reprint Very early scans for demonstrating dissemination in time in multiple sclerosis
    C Tur
    Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, Barcelona, Spain
    Mult Scler 14:631-5. 2008
    ....
  50. ncbi request reprint [Acute disseminated encephalomyelitis: study of factors involved in a possible development towards multiple sclerosis]
    C Tur
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona
    Neurologia 23:546-54. 2008
    ..Our work supports that also observed in recent publications: that both conversion to MS or presence of sequelae after an episode of ADEM are more frequent than traditionally considered...
  51. ncbi request reprint Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings
    J Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital Vall d Hebron, Escola d Infermeria, Barcelona, Espana
    Mult Scler 9:39-43. 2003
    ..The aim of this study was to investigate conversion to MS in patients with CISB...
  52. doi request reprint Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS
    Jaume Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, MS Centre of Catalonia, Hospital Universitari Vall d Hebron, EUI 2a planta, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neurol 257:742-6. 2010
    ..Results indicate that diplopia, facial sensory symptoms and gait disturbance occur in more than 30% of patients with CISB. Facial sensory symptoms are less associated with conversion to CDMS...
  53. ncbi request reprint Expression of chemokine receptors in the different clinical forms of multiple sclerosis
    E M Martínez-Cáceres
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 8:390-5. 2002
    ..These results support that chemokines and their receptors are involved in the pathogenesis of MS However, a pattem of chemokine-chemokine receptor expression characteristic of each clinical form of the disease failed to be observed...
  54. ncbi request reprint Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis
    I Pericot
    Unitat de Neuroimmunologia Clinica, Escola d enfermeria, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 9:256-9. 2003
    ..The relationship between multiple sclerosis (MS) and Sjögren syndrome (SS) is controversial. Nine patients, previously diagnosed with primary progressive MS (PPMS) and who fulfilled the diagnostic criteria for SS, are described...